Format

Send to

Choose Destination

See 1 citation in J Am Soc Nephrol 2016:

J Am Soc Nephrol. 2016 Oct;27(10):2929-2939. Epub 2016 Jun 9.

Current and Emerging Therapies for Lupus Nephritis.

Author information

1
Division of Nephrology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
2
Division of Nephrology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio Rovin.1@osu.edu.

Abstract

The introduction of corticosteroids and later, cyclophosphamide dramatically improved survival in patients with proliferative lupus nephritis, and combined administration of these agents became the standard-of-care treatment for this disease. However, treatment failures were still common and the rate of progression to ESRD remained unacceptably high. Additionally, treatment was associated with significant morbidity. Therefore, as patient survival improved, the goals for advancing lupus nephritis treatment shifted to identifying therapies that could improve long-term renal outcomes and minimize treatment-related toxicity. Unfortunately, progress has been slow and the current approaches to the management of lupus nephritis continue to rely on high-dose corticosteroids plus a broad-spectrum immunosuppressive agent. Over the past decade, an improved understanding of lupus nephritis pathogenesis fueled several clinical trials of novel drugs, but none have been found to be superior to the combination of a cytotoxic agent and corticosteroids. Despite these trial failures, efforts to translate mechanistic advances into new treatment approaches continue. In this review, we discuss current therapeutic strategies for lupus nephritis, briefly review recent advances in understanding the pathogenesis of this disease, and describe emerging approaches developed on the basis of these advances that promise to improve upon the standard-of-care lupus nephritis treatments.

KEYWORDS:

clinical trial; glomerular disease; immunosuppression; lupus nephritis; systemic lupus erythematosus

PMID:
27283496
PMCID:
PMC5042683
DOI:
10.1681/ASN.2016040415
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center